Omega-3 Content Confuses Consumers, Says GOED
Consumers knows omega-3s are good for them, but that’s about all they know on the topic, says the Global Organization for EPA and DHA Omega-3 (GOED; Salt Lake City).
SALT LAKE CITY-Consumers knows omega-3s are good for them, but that’s about all they know on the topic, says the Global Organization for EPA and DHA Omega-3 (GOED; Salt Lake City).
"Omega-3" is too broad to a term, GOED said, because it refers to three separate fatty acids -- EPA, DHA and ALA -- which do not perform in the same way.
"Consumers don't understand what it is," said Vivian Tysse, sales manager of Denomega (Norway).
ALA (alpha-linolenic acid), derived from plant sources such as flaxseed, can be labeled "omega-3", although it does not have the same nutritional content as EPA and DHA.
"Consumers don't really get the difference...it's EPA and DHA that your body really needs," said Ian Lucas, vice president of innovation and strategy at Ocean Nutrition Canada (Nova Scotia).
"Consumers need to be informed and make their own choice," said Philip Fass, executive director of industry and commercial relations at Martek Biosciences (Columbia, MD).
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
